Search Results - "Yay Donderici, Elifnur"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Future expenditure risk of silent members: a statistical analysis by Krause, Trudy Millard, Yay Donderici, Elifnur, Ganduglia Cazaban, Cecilia, Franzini, Luisa

    Published in BMC health services research (29-07-2016)
    “…Silent-members are members of a medical health plan who submit no claims for healthcare services in a benefit year despite 12 months of continuous-enrollment…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling by Powell, Adam C, Yay Donderici, Elifnur, Zhang, Nicole J, Forbes, Shaun P, Wiedower, Julie, McNeal, Amy C, Hiatt, Mark D

    “…Although immune checkpoint inhibitor immunotherapies are contraindicated as first-line treatment of advanced non-small cell lung cancer (NSCLC) in patients…”
    Get more information
    Journal Article
  4. 4
  5. 5

    AI-generated synthetic clinical-genomic data for precision oncology research: Validation using a case study on lung adenocarcinoma by Theodorou, Brandon, Das, Amar, Eagle, Craig, Sun, Jimeng, Hardin, Aaron, Zhang, Nicole, Yay Donderici, Elifnur

    Published in Journal of clinical oncology (01-06-2024)
    “…e13627 Background: The analysis of genomic variants is crucial in precision oncology research, offering insights into cancer risks and progression, especially…”
    Get full text
    Journal Article
  6. 6

    ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations by Severson, Paul, Sytnikova, Julia, Mohan, Adithi, Zhang, Nicole, Donderici, Elifnur Yay, Williams, Richard Thomas

    Published in Journal of clinical oncology (01-06-2023)
    “…3049 Background: FGFR2 and FGFR3 (FGFR2/3) gene alterations are oncogenic drivers found across various cancer types and have been successful targets of drug…”
    Get full text
    Journal Article
  7. 7

    Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers by Shariff, Bushra, Barnett, Reagan M, Dayyani, Farshid, Maron, Steven B, Mcgriskin, Rory, Klempner, Samuel, Donderici, Elifnur Yay, Zhang, Nicole, Masannat, Jude, Drusbosky, Leylah M, Mehta, Rutika

    Published in The oncologist (Dayton, Ohio) (05-08-2024)
    “…In addition to the existing biomarkers HER2 and PD-L1, FGFR2b has become an area of interest for the development of new targeted-based treatment. Given that…”
    Get full text
    Journal Article
  8. 8

    Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort by Heist, Rebecca Suk, Yu, Junhua, Donderici, Elifnur Yay, Zhang, Nicole, Espenschied, Carin R., Lang, Kathryn, Korytowsky, Beata, Chi, Andrew S., Christensen, James G

    Published in Journal of clinical oncology (20-05-2021)
    “…Abstract only 9106 Background: The introduction of KRAS G12C inhibitors into clinical trials has demonstrated promise and may provide a new therapeutic option…”
    Get full text
    Journal Article
  9. 9

    Abstract 4122: Occurrence of BRAF class II and III alterations is common across solid tumors and is associated with inferior clinical outcomes in NSCLC and melanoma by Severson, Paul L., Donderici, Elifnur Yay, Zhang, Nicole, Franovic, Aleksandra, Miller, Nichol, Martin, Eric, Murphy, Eric, Williams, Richard

    Published in Cancer research (Chicago, Ill.) (15-06-2022)
    “…Abstract Background: Oncogenic BRAF alterations can be categorized by their distinct structural and signaling properties which lead to activation of the MAPK…”
    Get full text
    Journal Article